EGFR酪氨酸激酶域基因变异及相关蛋白表达与gefitinib治疗晚期非小细胞肺癌疗效相关性的研究进展

Epidermal growth factor receptor tyrosine kinase domain gene mutation and correlated protein expression to gefitinib sensitivity in advanced non-small cell lung cancer

Gefitinib是一种选择性EGFR酪氨酸激酶抑制剂,是目前非小细胞肺癌(NSCLC)靶向治疗的热点之一,临床研究发现,患者对gefitinib的疗效有明显的差异。本文对EGFR基因及其蛋白与gefitinib疗效的相关性进行了回顾,探讨预示gefitinib疗效的标志物,有助于gefitinib在NSCLC治疗中的最优化使用。

Gefitinib, a selective EGFR tyrosine kinase inhibitor, is a targeted therapy in non - small cell lung cancer （NSCLC）. EGFR gene and proteins had been studied as response predictive markers for gefitinib, including mutations of EGFR gene, EGFR, P - EGFR, HER - 2, P - Akt, P - mTOR, P - FKHR, P - MAPK, P- Erk, P- STAT and so on. It is beneficial to choose patients who will response to gefitinib.